UK Antimicrobial Registry (UKAR)

UK Antimicrobial Registry (UKAR)


Duration: 5 years (start date November 2021)
Funder: British Society for Antimicrobial Chemotherapy
Chief investigators: Professor Gary MacfarlaneProfessor Gareth Jones
Other co-investigators: Professor Patrice Forget, Dr Callum Kaye (NHS Grampian), Dr Noha El Sakka (NHS Grampian)
Study coordinators: Laura Moir, Rebecca Parr
Project assistant: Jay Woods

Effective antimicrobial agents are a crucial component of modern medicine allowing the elimination or inhibition of growth of all microorganisms.  However, their effectiveness is threatened by evolutionary development of certain microbes.  According to the WHO, antimicrobial resistance is increasing world-wide, and compromising our ability to treat infectious diseases and undermining many other advances in health and medicine.  The purpose of the UKAR is to answer a broad set of research questions around novel anti-microbial agents.  It will allow us to describe the use of such novel agents throughout the UK and to quantify the clinical outcomes and safety profile associated with their use in a real world setting.

Enquiries about the study can be emailed to ukar@abdn.ac.uk.

You can find out more about the registry, including the latest study news, at the BSAC study webpages.

If you are a clinician who is interested in antimicrobial resistance, please follow the link or QR code below to the UKAR Study Expression of Interest form:

https://forms.office.com/UKAR-EOI